Andrew Boshara, MD
Advanced Heart Failure and Transplant Cardiology · Phoenix, AZNPI 1275917064
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,841 of the $13,739 with a category attached, or 86.2%. 32 manufacturers reported payments, led by Abbott at 46.9% of the total.
Across 274 payments — averaging $50.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$6K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Boehringer Ingelheim$945
- AstraZeneca$800
- Amgen$545
- Johnson & Johnson$485
- plus $3K from 26 others
What the payments were for
- Travel & lodging$1,58612%
- Food & beverage$11,84186%
- Education$3122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 106 | $6,447 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 31 | $1,226 |
| Boehringer Ingelheim | 12 | $945 |
| AstraZeneca | 13 | $800 |
| Amgen | 9 | $545 |
| Johnson & Johnson | 19 | $485 |
| Alnylam Pharmaceuticals Inc. | 11 | $481 |
| Endotronix, Inc. | 1 | $424 |
| Novartis | 17 | $422 |
| Pfizer | 12 | $413 |
| Abiomed | 5 | $337 |
| E.r. Squibb & Sons, L.L.C. | 5 | $296 |
| Novo Nordisk | 1 | $119 |
| Esperion Therapeutics, Inc. | 1 | $115 |
| Actelion Pharmaceuticals US, Inc. | 4 | $113 |
| Kestra Medical Technology Services, Inc. | 4 | $68 |
| ZOLL Respicardia, Inc. | 4 | $68 |
| Procyrion, Inc. | 2 | $48 |
| Atricure, Inc. | 1 | $43 |
| Irhythm Technologies, Inc. | 2 | $38 |
| Impulse Dynamics (USA) Inc. | 2 | $36 |
| Boston Scientific | 1 | $35 |
| Teleflex LLC | 1 | $33 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $33 |
| Medtronic | 1 | $31 |
| Livanova USA, Inc. | 1 | $27 |
| Cvrx, Inc. | 1 | $25 |
| Edwards Lifesciences | 1 | $23 |
| Bayer | 1 | $17 |
| Philips North America LLC | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$2,029
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,980
- JARDIANCE$624
- LifeVest$432
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$424
- Repatha$364
- VYNDAQEL$247
- CAMZYOS$239
- ENSITE PRECISION$198
- CardioMEMS HF System$155
- FARXIGA$152
- Impella$146
- LEQVIO$139
- ENTRESTO$139
- HeartMate 3 Left Ventricular Assist Device$135
- Xience Sierra Coronary Stent System$122
- XARELTO$121
- ONPATTRO$120
- Ozempic$119
- NEXLIZET$115
How this compares
Too few advanced heart failure and transplant cardiology providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 33 | $30,273 |
| FarxigaDapagliflozin Propanediol | 37 | $26,316 |
| JardianceEmpagliflozin | 16 | $11,917 |
| Bumetanide | 12 | $457 |
| Metoprolol Succinate | 17 | $447 |
| Spironolactone | 49 | $271 |
| Carvedilol | 24 | $241 |
| ClopidogrelClopidogrel Bisulfate | 11 | $136 |
| Rosuvastatin Calcium | 11 | $119 |
| Atorvastatin Calcium | 14 | $112 |
| Furosemide | 11 | $18 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $422 | $30,27333 claims |
| AstraZenecaFarxiga | $800 | $26,31637 claims |
| Boehringer IngelheimJardiance | $945 | $11,91716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Phoenix
- David SteidleyPhoenix$57K
- Radha GopalanPhoenix$32K
- Suresh YerraPhoenix$1K
- Anantharam KalyaPhoenix$1K
- Anita PhancaoTucson$31K
- Geoffrey JaoScottsdale$21K
- Carl TongTucson$346
- Wassim AssaadScottsdale$313
- Katie MurphyScottsdale$305
- Sharon PowellTucson$289
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.